Why is Abbott separating its Nutrition business?

Abbott is separating its Nutrition business because it has a unique opportunity to capitalize on consumer trends in healthy nutrition. As an independent company, it can better focus its resources on innovation and growth in its specific market. This also allows Abbott to concentrate on its core higher-growth, innovation-driven healthcare portfolio.

What will the new Nutrition company focus on and what brands will it include?

The new Nutrition company will be a global leader in the healthy nutrition market, with approximately $8.5 billion in annual sales. It will feature iconic brands such as Similac, PediaSure, Pedialyte, Glucerna, and Ensure, and will focus on areas like metabolic health, prevention, and wellness.

What will Abbott look like after the separation?

After the separation, Abbott will remain a large, diversified healthcare company with approximately $42 billion in sales. Its focus will be on market-leading positions in cardiovascular and neuromodulation devices, biowearables, diagnostics, and established medicines.

How will the separation affect Abbott shareholders?

Abbott intends to separate the Nutrition business through a distribution of shares to its current shareholders. This means shareholders will own shares in both the remaining Abbott company and the newly independent Nutrition company. The combined dividend is expected to be equal to Abbott's dividend at the time of separation.

When is the separation expected to be completed?

Abbott expects to complete the transaction by the end of 2027, subject to customary conditions, including regulatory approvals and final board approval.

ABT 8-K SEC Disclosure — Oct 21, 2026

01—Abstract

Summary

Summary of the 8-K filed October 21, 2026. Cited figures are marked; the original filing is the authoritative source.

Abbott Laboratories (ABT) announced its intention to separate its global Nutrition business into an independent, publicly traded company.

This strategic move aims to unlock distinct growth and value-creation opportunities for both the standalone Nutrition entity and the remaining Abbott healthcare business. The new Nutrition company is projected to have approximately $8.5 billion^a in annual sales and will focus on the rapidly growing healthy nutrition market with iconic brands like Similac, PediaSure, and Ensure. Following the separation, Abbott will continue as a diversified healthcare leader with approximately $42 billion in sales, concentrating on its higher-growth, innovation-driven portfolio in medical devices, diagnostics, and established medicines.

The separation is anticipated to be completed by the end of 2027 and is structured as a tax-free distribution of shares to Abbott shareholders, who will then own stakes in both entities. This move is expected to allow for more aligned capital allocation and distinct strategic focus for each business.

02—Key points

Key Highlights

Abbott plans to separate its Nutrition business into an independent, publicly traded company.
The new Nutrition company is expected to generate approximately $8.5 billion in annual sales and lead the healthy nutrition market.
Key nutrition brands include Similac, PediaSure, Pedialyte, Glucerna, and Ensure.
Abbott will retain a focused portfolio of approximately $42 billion in sales, emphasizing medical devices, diagnostics, and established medicines.
The separation is intended to be a tax-free distribution of shares to Abbott shareholders.
Completion of the separation is targeted for the end of 2027, subject to customary conditions and approvals.
The transaction is not expected to impact Abbott's current guidance for 2026 or 2027.

03—Questions

Frequently Asked Questions

Why is Abbott separating its Nutrition business?
Abbott is separating its Nutrition business because it has a unique opportunity to capitalize on consumer trends in healthy nutrition. As an independent company, it can better focus its resources on innovation and growth in its specific market. This also allows Abbott to concentrate on its core higher-growth, innovation-driven healthcare portfolio.
What will the new Nutrition company focus on and what brands will it include?
The new Nutrition company will be a global leader in the healthy nutrition market, with approximately $8.5 billion in annual sales. It will feature iconic brands such as Similac, PediaSure, Pedialyte, Glucerna, and Ensure, and will focus on areas like metabolic health, prevention, and wellness.
What will Abbott look like after the separation?
After the separation, Abbott will remain a large, diversified healthcare company with approximately $42 billion in sales. Its focus will be on market-leading positions in cardiovascular and neuromodulation devices, biowearables, diagnostics, and established medicines.
How will the separation affect Abbott shareholders?
Abbott intends to separate the Nutrition business through a distribution of shares to its current shareholders. This means shareholders will own shares in both the remaining Abbott company and the newly independent Nutrition company. The combined dividend is expected to be equal to Abbott's dividend at the time of separation.
When is the separation expected to be completed?
Abbott expects to complete the transaction by the end of 2027, subject to customary conditions, including regulatory approvals and final board approval.

04—Continue

← View all 8-K filings